ÎÚÑ»´«Ã½

A Game Changer for Follicular Lymphoma: Mastering Use of Precision Therapies as Part of a Chemo-free Treatment Paradigm

This program is supported by AstraZeneca, Genmab US, Inc. and Ipsen Biopharmaceuticals, Inc. Provided by Clinical Care Options, LLC in partnership with the Follicular Lymphoma Foundation.

¶Ù±ð³¦±ð³¾²ú±ð°ùÌý06,Ìý2024
11:00 a.m. - 2:00 p.m. Pacific time
Manchester Grand Hyatt San Diego
Grand Hall C

Join CCO and The Follicular Lymphoma Foundation for an engaging symposium reviewing the latest advancements in relapsed/refractory (R/R) Follicular Lymphoma (FL) management. This dynamic event combines interactive case challenges, patient survey insights, and expert panel discussions, offering a comprehensive look at cutting-edge treatments and strategies. Engage directly with leading experts through multiple Q&A sessions, where you can present your questions and real-world cases for personalized guidance. Navigate the evolving landscape of R/R FL treatment, explore the implementation of the newest therapies, and gain insights into future strategies heading into 2025. This symposium promises to enrich your understanding of R/R FL, challenge your clinical acumen, and empower you to apply the latest knowledge in your practice. Contribute to thought-provoking dialogues on R/R FL, shaping the discourse and enhancing collective expertise in this critical field.

Chair:

Sonali M. Smith, MD
University of Chicago
Chicago,  IL

Speakers:

Caron A. Jacobson, MD, MMSc
Dana-Farber Cancer Institute
Boston,  MA

±Ê±ð³Ù±ð°ùÌý²Ñ²¹°ù³Ù¾±²Ô,Ìý²Ñ¶Ù
Weill Cornell Medicine
New York,  NY

Ishana Fleurant, Clinical Care Options
Email: [email protected]

A New Era for Hemophilia Treatment: Common Goals, Unique Perspectives

This program is supported by Sanofi

¶Ù±ð³¦±ð³¾²ú±ð°ùÌý06,Ìý2024
11:00 a.m. - 2:00 p.m. Pacific time
Marriott Marquis San Diego Marina
Pacific Ballroom Salons 21-22

The session will focus on how new and emerging therapies for hemophilia will address the numerous unmet needs of patients, and will include expert presentations alongside panel-based discussions between two presenting faculty, who will be experts in hemophilia treatment, and three contributing faculty, who will be representatives of the HTC care team, including a community-based physician, a hemophilia nurse, and a patient with hemophilia. The content is designed to explore common questions, concerns, and insights from a variety of perspectives within the hemophilia community, allowing the new and emerging therapeutic landscape to be explored in a practice-relevant manner.

Chairs:

Stacy E. Croteau, MD, MMS
Dana-Farber/Boston Children's Cancer and Blood Disorders Center
Boston,  MA

³Ò³Ü²âÌý³Û´Ç³Ü²Ô²µ,Ìý²Ñ¶Ù
Children's Hospital Los Angeles
Los Angeles,  CA

Speakers:

°ä´Ç±ô±ðÌý°­°ù³Ü²õ±ð
Lived Experience Expert
Martinsville,  IN

Jennifer Maahs, RN, PNP, MSN
Indiana Hemophilia and Thrombosis Center
Indianapolis,  IN

´³±ð²Ô²Ô²âÌý²Ñ³¦¶Ù²¹²Ô¾±±ð±ô,Ìý²Ñ¶Ù
Novant Health Hemby Children's Hospital
Charlotte,  NC

Janis Vajdos, The France Foundation
Email: [email protected]

A Violent Graft in a Vulnerable Host: The Future of aGVHD Management

This program is supported by an independent educational grant from CSL Behring LLC. Provided by RMEI Medical ÎÚÑ»´«Ã½, LLC.

¶Ù±ð³¦±ð³¾²ú±ð°ùÌý06,Ìý2024
11:00 a.m. - 2:00 p.m. Pacific time
San Diego Convention Center
Room 29

In this activity, an interprofessional expert panel discusses the role of the interprofessional care team in the prophylaxis and management of acute graft-versus-host disease (aGVHD) according to current guidelines and available agents. The panel will also discuss emerging novel therapies for aGVHD prevention and treatment and hear from an experienced patient.

Chair:

Sung W. Choi, MD, MS
University of Michigan
Ann Arbor,  MI

Speakers:

±Ê²¹³Ü±ôÌý°ä²¹³¾±è²ú±ð±ô±ô
Patient Speaker
Ann Arbor,  MI

Chelsea Honstain, MS, FNP-C
University of Michigan Health
Ann Arbor,  MI

³Ò¾±²¹²Ô²Ô¾±Ìý³§³¦²¹±è±è²¹³Ù¾±³¦³¦¾±
University of Michigan
Ann Arbor,  MI

Lisa Pagliaccetti, RMEI Medical ÎÚÑ»´«Ã½, LLC
Email: [email protected]

Addressing Current Questions and Controversies in the Management of Myelofibrosis - What Clinicians Want to Know

This program is supported by educational grants from CTI BioPharma, a Sobi Company, Geron Corporation, GSK, Incyte Corporation and Karyopharm Therapeutics

¶Ù±ð³¦±ð³¾²ú±ð°ùÌý06,Ìý2024
11:00 a.m. - 2:00 p.m. Pacific time
Manchester Grand Hyatt San Diego
Seaport Ballroom EFGH

This 2-hour CME-accredited activity – offered to both in-person and virtual attendees – will focus on the management of patients with myelofibrosis. Four clinical investigators will serve as faculty for the program, one of whom will moderate. To create a relevant agenda, prior to the symposium Research To Practice (RTP) will recruit 50 general medical oncologists/hematologists to complete a survey designed to evaluate their educational interests and knowledge deficiencies related to the treatment of myelofibrosis. During the symposium, selected results from the survey highlighting areas of greatest interest will be presented. The faculty members will then review relevant research findings, discuss evidence-based treatment approaches and provide perspectives on ongoing studies. Actual questions contributed by the survey respondents as well as audience members will be integrated into the proceedings. The live activity will be recorded and developed into an enduring CME resource and promoted by RTP to 46,500 subscribers worldwide.

Chair:

Andrew T. Kuykendall, MD
H. Lee Moffitt Cancer Center and Research Institute
Tampa,  FL

Speakers:

±Ê°ù¾±³Ù³ó±¹¾±°ù²¹ÂáÌýµþ´Ç²õ±ð,Ìý²Ñ¶Ù
The University of Texas MD Anderson Cancer Center
Houston,  TX

Angela G. Fleischman, MD, PhD
University of California, Irvine
Irvine,  CA

´¡²ú»å³Ü±ô°ù²¹³ó±ð±ð³¾Ìý³Û²¹³¦´Ç³Ü²ú,Ìý²Ñ¶Ù
University of Kansas Cancer Center
Leawood,  KS

Sylvia Eriksen, Research To Practice
Email: [email protected]

Addressing Current Questions and Controversies Regarding the Role of CAR T-Cell Therapy and Bispecific Antibodies in the Management of Lymphoma - What Clinicians Want to Know

This program is supported by educational grants from Bristol Myers Squibb, Genentech, a member of the Roche Group and Regeneron Pharmaceuticals Inc.

¶Ù±ð³¦±ð³¾²ú±ð°ùÌý06,Ìý2024
11:00 a.m. - 2:00 p.m. Pacific time
Manchester Grand Hyatt San Diego
Seaport Ballroom ABCD

This 2-hour CME-accredited activity – offered to both in-person and virtual attendees – will focus on the utilization of CAR T-cell therapy and bispecific antibodies in the care of patients with non-Hodgkin lymphoma. Five clinical investigators will serve as faculty for the program, one of whom will moderate. Prior to the symposium. Research To Practice (RTP) recruit 4 general medical oncologists/hematologists to consult on the project. The clinicians will participate in a working group session during which they will voice challenging questions and cases from their practices and help shape the content for the symposium. The entire session will be recorded and video segments will be adapted for presentation during the event. The agenda for the symposium will be divided into 5 modules. To begin each module, the moderator will play select video excerpts from the working group for the audience and the faculty. Moderated panel discussion will ensue to provide expert perspectives and answers to the questions introduced. A faculty member-led review of related research findings will complete each module. To make the event even more engaging, attendees will use iPads to submit their own questions and cases. Virtual attendees will have the same capability via the webcast platform.

Chair:

Jeremy S. Abramson, MD
Massachusetts General Hospital Cancer Center
Boston,  MA

Speakers:

Jennifer L. Crombie, MD
Dana-Farber Cancer Institute
Boston,  MA

Martin Hutchings, MD, PhD
Copenhagen University Hospital - Rigshospitalet
Copenhagen,  Denmark

²Ñ²¹³Ù³Ù³ó±ð·ÉÌý³¢³Ü²Ô²Ô¾±²Ô²µ,Ìý¶Ù°¿
University of Nebraska Medical Center
Omaha,  NE

Tycel J. J. Phillips, MD
City of Hope
Duarte,  CA

Sylvia Eriksen, Research To Practice
Email: [email protected]

Advances in the Management of Myeloproliferative Neoplasms and Systemic Mastocytosis: Diagnosis/Classification, Risk Stratification, and Optimal Therapeutic Selection

This program is supported by Blueprint Medicines Corporation; CTI BioPharma Corp., a Sobi Company; Incyte Corporation; and PharmaEssentia Corporation

¶Ù±ð³¦±ð³¾²ú±ð°ùÌý06,Ìý2024
11:00 a.m. - 2:00 p.m. Pacific time
Manchester Grand Hyatt San Diego
Grand Hall B

This symposium is CME-certified and will be presented live on Friday, December 6, 2024.

This activity is provided by HMP ÎÚÑ»´«Ã½.

The live portion of this symposium will be presented as a live 2-hour Friday Satellite Symposium (FSS) held prior to the ASH Annual Meeting. This live educational activity will feature key experts in the field of MPNs/SM who will use an interactive, case-based approach to explore personalized care across the treatment continuum. This activity is designed to provide clinicians with the latest trial data, real-world evidence, and clinical practice guidelines to ensure timely and accurate diagnosis of MPNs/SM, an understanding of SM variants and genetic mutations, and utilization of a patient-centered treatment approach to optimize therapeutic selection and manage treatment-related adverse events.

Throughout this educational session, discussion spurred by patient cases, continuous clinical practice polling questions, and a live Q&A session will enhance learner engagement.

Chair:

John O. Mascarenhas, MD
Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
New York,  NY

Speakers:

Mariana Castells, MD, PhD
Department of Medicine, Division of Allergy and Clinical Immunology, Brigham and Women’s Hospital
Boston,  MA

Daniel J. DeAngelo, MD
Dana-Farber Cancer Institute
Boston,  MA

Raajit Rampal, MD, PhD
Memorial Sloan Kettering Cancer Center
New York,  NY

Kristin Ciszeski, HMP Global
Email: [email protected]

Application of Evolving Evidence in Mantle Cell Lymphoma: Therapeutic Strategies Using BTK Inhibitors

This program is supported by AstraZeneca. Provided by Clinical Care Options, LLC

¶Ù±ð³¦±ð³¾²ú±ð°ùÌý06,Ìý2024
11:00 a.m. - 2:00 p.m. Pacific time
Manchester Grand Hyatt San Diego
Grand Hall D

The care of patients with mantle cell lymphoma (MCL) is becoming increasingly complex with new indications for BTK inhibitors and emerging data transforming management strategies. CCO proudly presents this live interactive symposium, designed to equip clinicians with the knowledge and insights needed to confidently navigate the rapidly evolving landscape of MCL patient care. Engage directly with leading experts through Q&A sessions, patient case discussions, and review of a 2025 MCL treatment algorithm. These interaction with the panelests will enhance your understanding and application of cutting-edge treatments for both newly-diagnosed and R/R disease. Join us for a dynamic and informative experience that will empower you to implement the latest treatment advances in BTK inhibitors for MCL and improve patient outcomes.

Chair:

Julie M. Vose, MD, MBA
University of Nebraska Medical Center
Omaha,  NE

Speakers:

Brad S. Kahl, MD
Washington University School of Medicine in St. Louis
St. Louis,  MO

John P. Leonard, MD
Weill Cornell Medicine
New York,  NY

Ishana Fleurant, Clinical Care Options
Email: [email protected]

Collaborating for Optimal Immune Thrombocytopenia Care: Uniting Disease, Treatment, and Patient-Centered Considerations

This program is supported by SOBI, Novartis, and Rigel Pharmaceuticals, Inc.

¶Ù±ð³¦±ð³¾²ú±ð°ùÌý06,Ìý2024
11:00 a.m. - 2:00 p.m. Pacific time
Marriott Marquis San Diego Marina
Marriott Grand Ballroom 11-13

Expert faculty will focus on the important pillars related to the comprehensive and holistic care of patients with ITP, including disease-centered care, treatment-related considerations, and prioritizing patient-centered care. Faculty will expand on the mechanism of the disease and its causes, and the importance of a holistic approach. Presentations will revolve around the importance of defining clinical features and diagnostic criteria that are critical to diagnosis and treatment planning. A collaborative panel discussion will include insights into efficacy and safety data on current treatment options, choosing the best option for patients, and managing adverse events. In addition, the importance of patient perspectives and the caregiver’s roles will be discussed and how they can be integrated into collaborative decision-making.

Speakers:

±á²¹²Ô²Ô²âÌý´¡±ô-³§²¹³¾°ì²¹°ù¾±,Ìý²Ñ¶Ù
Massachusetts General Hospital
Cambridge,  MA

Rachael F. Grace, MD, MMSc
Dana-Farber/Boston Children's Cancer and Blood Disorders Center
Boston,  MA

Michael D Tarantino, MD
Bleeding and Clotting Disorders Institute
Peoria,  IL

Vikki Chavis, Medscape
Email: [email protected]

Crafting Custom Care in CLL: Guidance on Upfront and Sequential Treatment Decisions With Targeted and Immune-based Platforms

This program is supported by AstraZeneca, BeiGene, Janssen and Lilly

¶Ù±ð³¦±ð³¾²ú±ð°ùÌý06,Ìý2024
11:00 a.m. - 2:00 p.m. Pacific time
Marriott Marquis San Diego Marina
San Diego Ballroom AB

This CME/MOC/AAPA/IPCE activity is provided by PVI, PeerView Institute for Medical ÎÚÑ»´«Ã½ and developed with our educational partner, CLL Society.

This activity is supported by independent educational grants from AstraZeneca, BeiGene, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Lilly.

In collaboration with CLL Society, PeerView’s unique Clinical Consults event will provide useful information and practical instruction in an engaging, interactive manner designed to explore the rapid transformation of modern CLL therapy. Expert conversations on treatment choices will be paired with practically-oriented case discussions to provide learners with guidance on addressing common clinical challenges arising from the upfront and sequential management of CLL to strategies for integrating emerging, innovative modalities into care. Throughout, the experts will cover:

• Evidence supporting the personalized selection of continuous SOC BTKi or finite 1L regimens;
• The ongoing experience with BTKi-BCL2i combinations;
• Sequential therapy with ncBTKi options and CAR-T immunotherapy in R/R disease;
• Newer modalities such as emerging ncBTKi, next-gen BCL2i, BTK degraders, dual c/ncBTKi, and bispecific antibodies in challenging pre-treated and double-exposed populations.

Don’t miss this opportunity to upgrade your skills in customizing CLL care!

Chair:

Prof. John G. Gribben, MD, DSc
Barts Cancer Institute, Barts and The London School of Medicine, Queen Mary, University of London
London,  United Kingdom

Speakers:

Matthew S. Davids, MD, MMSc
Dana-Farber Cancer Institute, Harvard Medical School
Boston,  MA

±·¾±³¦´Ç±ô±ðÌý³¢²¹³¾²¹²Ô²Ô²¹,Ìý²Ñ¶Ù
Herbert Irving Comprehensive Cancer Center, New York-Presbyterian/Columbia University Medical Center
New York,  NY

Meghan C. Thompson, MD
Memorial Sloan Kettering Cancer Center
New York,  NY

Lauren Wilkes, PVI, PeerView Institute for Medical ÎÚÑ»´«Ã½
Email: [email protected]

Emerging insights in biology and treatment approaches to Peripheral T cell Lymphomas

This program is supported by Acrotech Biopharma

¶Ù±ð³¦±ð³¾²ú±ð°ùÌý06,Ìý2024
11:00 a.m. - 2:00 p.m. Pacific time
Marriott Marquis San Diego Marina
Pacific Ballroom Salons 18-19

Peripheral T-cell lymphoma (PTCL) represents a group of heterogeneous and aggressive non-Hodgkin lymphomas with generally poor prognosis. Despite advances in understanding the underlying biology, treatment outcomes have remained suboptimal. This symposium, supported by Acrotech, and provided by the University of Texas MD Anderson Cancer Center with MD ÎÚÑ»´«Ã½, will explore groundbreaking therapies and the shifting paradigm in PTCL treatment. Renowned experts will dissect the complexity of PTCL biology, discuss innovative therapeutic strategies, and address the challenges faced in clinical practice. Presentations will include insights into nodal T-cell lymphoma epigenetics, CAR-T cell therapy applications, and novel approaches for rare PTCL subtypes. This educational event promises to answer pivotal questions in PTCL management, focusing on improving patient outcomes and quality of life. With a blend of didactic sessions, interactive panels, and case studies, attendees will be at the forefront of translating emerging research into transformative patient care.

Chair:

Swami P. Iyer, MD
The University of Texas MD Anderson Cancer Center
Houston,  TX

Speakers:

Kate Cwynarski, MBBS, PhD, FRCP, FRCPath
University College London Hospital
London,  United Kingdom

³¢³Ü¾±²õÌý²Ñ²¹±ô±è¾±³¦²¹,Ìý²Ñ¶Ù
The University of Texas MD Anderson Cancer Center
Houston,  TX

Yun Kyoung Tiger, MD, PhD
Rutgers Robert Wood Johnson Medical School
New Brunswick,  NJ

´³²¹²õ³¾¾±²Ô±ðÌý´Ü²¹¾±²Ô,Ìý²Ñ¶Ù
City of Hope
Duarte,  CA

Christopher Bolwell, MD ÎÚÑ»´«Ã½
Email: [email protected]

Escape the Amyloid Maze: Unraveling Data and Care Strategies for AL Amyloidosis

This program is supported by Prothena, Janssen and Alexion

¶Ù±ð³¦±ð³¾²ú±ð°ùÌý06,Ìý2024
11:00 a.m. - 2:00 p.m. Pacific time
Marriott Marquis San Diego Marina
Marriott Grand Ballroom 8-9

This 90-minute symposium will feature 3 multidisciplinary expert faculty. The symposium is designed to engage attendees in an interactive experience focused on key challenges and therapeutic advances in the management of AL amyloidosis. The overall goal of this symposium is for learners to be better able to integrate evidence-based strategies for the optimal care of patients with AL amyloidosis.

Chair:

Morie A. Gertz, MD
Mayo Clinic
Rochester,  MN

Speakers:

Suzanne Lentzsch, MD, PhD
Columbia University Herbert Irving Comprehensive Cancer Center
New York,  NY

³Õ²¹¾±²õ³ó²¹±ô¾±Ìý³§²¹²Ô³¦³ó´Ç°ù²¹·É²¹±ô²¹
Boston University Chobanian and Avedisian School of Medicine and Boston Medical Center
Boston,  MA

Vikki Chavis, Medscape
Email: [email protected]

Evolving Treatment Paradigms for Patients with Hemoglobinopathies

This program is supported by Vertex Pharmaceuticals

¶Ù±ð³¦±ð³¾²ú±ð°ùÌý06,Ìý2024
11:00 a.m. - 2:00 p.m. Pacific time
San Diego Convention Center
Room 30

The most common monogenic global disorders worldwide are hemoglobinopathies, genetic diseases related to hemoglobin (Hb) synthesis. The genetic cause of hemoglobinopathies are DNA variants in or near the globin genes. It has been estimated that 7% of the global population carry a DNA variant, with the majority of diagnosed individuals having sickle cell disease, and the minority are affected by ß-thalassemia. Though diverse, the burden of hemoglobinopathies is known to be severe and disabling for many individuals, requiring specialized multidisciplinary management. This accredited symposium will feature engaging, case-based discussions among 4 experts highlighting clinical trial data for gene therapies and strategies for integrating gene therapy into the individualized management of hemoglobinopathies, including sickle cell disease and transfusion-dependent thalassemia.

Chair:

µþ¾±°ù±ð±ðÌý´¡²Ô»å±ð³¾²¹°ù¾±²¹³¾,Ìý²Ñ¶Ù
University of Connecticut Health
West Hartford,  CT

Speakers:

Farzana Sayani, MD, MSc
University of Pennsylvania
Philadelphia,  PA

³§³ÜÂá¾±³ÙÌý³§³ó±ð³Ù³ó,Ìý²Ñ¶Ù
Weill Cornell Medicine
New York,  NY

Kelly McGregor, MJH Events
Email: [email protected]

From Barriers to Breakthroughs in Multiple Myeloma: How Trials Compare to the Real-World Management of Patients in Your Practice

This program is supported by Sanofi and Takeda Pharmaceuticals USA, Inc.

¶Ù±ð³¦±ð³¾²ú±ð°ùÌý06,Ìý2024
11:00 a.m. - 2:00 p.m. Pacific time
San Diego Convention Center
Room 6A

• The live portion will be presented as a 3.0-hour Satellite Symposium held prior to the 2024 ASH Annual Meeting.
  • This satellite program will bring together four experts to highlight novel agents in the management of MM, including the latest clinical trial data and strategies to manage ND, and R/R MM including a discussion of the latest data
  • The program will also integrate a real-world component to highlight how these case scenarios are handled in the community, to shed light on the potential gaps between clinical trial experience and real world application. PER will identify community oncologists who will submit pre-recorded videos explaining their challenges and barriers to care. Following these real-world videos, experts will propose solutions to be applied to bridge the gaps. Learners will also be given the chance to bring forward their own challenges.
• To further enhance the integration of recent data into practice, the program will feature an interactive question-and-answer session between the faculty and attendees to emphasize areas of educational need, highlight areas of debate, and illustrate the application of new data in defined clinical situations.
• The program will also be live-streamed on our website for the benefit of those unable to attend in person.

Chair:

Krina K. Patel, MD, MSc
The University of Texas MD Anderson Cancer Center
Houston,  TX

Speakers:

Alfred L. Garfall, MD
University of Pennsylvania Abramson Cancer Center
Philadelphia,  PA

Ajay K. Nooka, MD, MPH
Department of Hematology and Medical Oncology, Winship Cancer Institute, School of Medicine, Emory University
Atlanta,  GA

Kelly McGregor, MJH Events
Email: [email protected]

Guiding Our Patient's Path: Managing First Relapse in Diffuse Large B-Cell Lymphoma Outside of CAR Ts

This program is supported by F. Hoffmann-La Roche Ltd

¶Ù±ð³¦±ð³¾²ú±ð°ùÌý06,Ìý2024
11:00 a.m. - 2:00 p.m. Pacific time
Marriott Marquis San Diego Marina
Marriott Grand Ballroom 2-4

Medscape has identified several key focus areas to address during the Symposium taking place at ASH 2024 on the 6th of December in San Diego:

• Understanding treatment goals and treatment options for patients with diffuse large B-cell lymphoma (DLBCL) at first relapse where transplant and CAR T-cell therapy are not a suitable option
• Consideration of the patient perspective of living with relapsed or refractory (R/R) DLBCL and how to effectively communicate with patients to ensure shared decision-making when selecting therapy
• Appreciation of the value of bispecific antibodies for the current management of R/R DLBCL and considerations for earlier use at first relapse

Chair:

°Â±ð²Ô»å²âÌý°¿²õ²ú´Ç°ù²Ô±ð,Ìý²Ñ¶Ù
Newcastle Hospitals NHS Trust
Newcastle Upon Tyne,  United Kingdom

Speakers:

±·²¹³Ù²¹³¦³ó²¹Ìýµþ´Ç±ô²¹Ã±´Ç²õ
Patient Advocate
Madrid,  Spain

Gareth P. Gregory, MBBS(Hons), PhD, FRACP, FRCPA
School of Clinical Sciences at Monash Health, Monash University
Melbourne,  Australia

Gilles Salles, MD, PhD
Lymphoma Service Chief, Memorial Sloan Kettering Cancer Center
New York,  NY

Vikki Chavis, Medscape
Email: [email protected]

Maximizing Touchpoints to Empower Impactful Patient-Centered Care for Paroxysmal Nocturnal Hemoglobinuria

This program is supported by Alexion and Novartis

¶Ù±ð³¦±ð³¾²ú±ð°ùÌý06,Ìý2024
11:00 a.m. - 2:00 p.m. Pacific time
Marriott Marquis San Diego Marina
Marriott Grand Ballroom 5-6

This interactive, live symposium will focus on all aspects of PNH through the lens of the patient journey. Expert faculty will review the complement pathway, highlight diagnostic challenges, and discuss current and emerging treatment options, while listening to a patient share their experiences. A collaborative approach to patient care will be a key focus of the presentation as faculty prioritize care and quality of life for patients with PNH.

Speakers:

³§°ù¾±°ì²¹²Ô³Ù³óÌý±·²¹²µ²¹±ô±ô²¹
Baptist Health South Florida
Miami,  FL

Christopher Patriquin, MD, MSc, FRCPC
Division of Medical Oncology and Hematology, University Health Network
Toronto,  ON, Canada

Vikki Chavis, Medscape
Email: [email protected]

Medical Crossfire®: Bridging Evidence to Practice in AML... Updates on FLT3, IDH1/2, Maintenance, Combos, and Clinical Trials

This program is supported by Bristol Myers Squibb; Jazz Pharmaceuticals; Kura Oncology, Inc.; Rigel Pharmaceuticals, Inc.; and Syndax Pharmaceuticals, Inc.

¶Ù±ð³¦±ð³¾²ú±ð°ùÌý06,Ìý2024
11:00 a.m. - 2:00 p.m. Pacific time
San Diego Convention Center
Ballroom 20CD

To maximize the clinical outcomes for individual patients, practicing healthcare professionals must have mastered how to leverage the evidence and possess the competence to apply treatment guidelines and the latest emerging data with regard to the many recent approvals in this therapeutic space. To ensure competence and improve patient outcomes, strategic educational programming is necessary. This program will focus on how to best leverage emerging evidence for currently available therapies and proactively manage and mitigate treatment-related toxicities.

Chair:

±·²¹±¹²¹±ôÌý¶Ù²¹±¹±ð°ù,Ìý²Ñ¶Ù
The University of Texas MD Anderson Cancer Center
Houston,  TX

Speakers:

´³±ð²õ²õ¾±³¦²¹Ìý´¡±ô³Ù³¾²¹²Ô,Ìý²Ñ¶Ù
Professor of Medicine, Hematology Oncology Division, Northwestern University
Chicago,  IL

Amir T. Fathi, MD
Massachusetts General Hospital Cancer Center
Boston,  MA

Gail J. Roboz, MD
Weill Cornell Medicine/New York Presbyterian Hospital
New York,  NY

Joshua F. Zeidner, MD
University of North Carolina
Chapel Hill,  NC

Kelly McGregor, MJH Events
Email: [email protected]

Next Up: Conversations On Optimizing CD38 Antibody-Based Triplet Regimens For Early-Relapse Multiple Myeloma

This program is supported by Sanofi

¶Ù±ð³¦±ð³¾²ú±ð°ùÌý06,Ìý2024
11:00 a.m. - 2:00 p.m. Pacific time
San Diego Convention Center
Room 6B

They've become a game-changer in early relapse multiple myeloma: anti-CD38–based triplet regimens. These therapies have the potential to improve outcomes AND optimize quality of life. But do you know how to incorporate performance status, relapse aggressiveness, cytogenetics, and other patient-centered factors to tailor your treatment approach? Two myeloma experts will spend 60 minutes in a lively discussion and case-based debate on the latest updates in anti-CD38–based triplets for relapsed/refractory myeloma. They will also discuss best practices to promote diversity, equity, and inclusion in myeloma care. Then, a patient will join the experts to recount the highs and lows of their journey living with myeloma, and how their mindset prepared them for their fight against cancer.

Join our closing live Q&A to challenge our experts and enhance your understanding of these therapies. Connect with experts, stay informed, and be part of the RRMM care revolution!

Chair:

Thomas G. Martin, MD
Professor University of California, San Francisco, Associate Chief, Hematology/Oncology
San Francisco,  CA

Speakers:

°­±ð²Ô²Ô±ð³Ù³óÌý°ä²¹±è±è²õ,Ìý´³¶Ù
Patient Advocate
Asheville,  NC

Carlyn Rose Tan, MD
Memorial Sloan Kettering Cancer Center
New York,  NY

Emilie Desse, Answers in CME
Email: [email protected]

Treatment Crossroads: Diverse Perspectives on Treatment Strategies for Relapsed/Refractory DLBCL and FL

This program is supported by PRIME ÎÚÑ»´«Ã½, LLC

¶Ù±ð³¦±ð³¾²ú±ð°ùÌý06,Ìý2024
11:00 a.m. - 2:00 p.m. Pacific time
San Diego Convention Center
Room 6DE

Join expert faculty as they take a deep dive into the latest clinical evidence and practical considerations for treatment of complex cases of patients with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). Informed by real-world data on top challenges regarding the selection, sequencing and integration of novel therapies in DLBCL management plans, this satellite symposium will support lymphoma care teams in examining the latest evidence, differentiating new and emerging novel CAR T-cell and bispecific antibody therapies for DLBCL and FL, and addressing barriers to novel therapy adoption. The topics for discussion by the expert faculty panel will be supported by clinical cases and enhanced by interactive polling questions and live questions submitted by attendees throughout the presentation. Altogether, this satellite symposium will harness real-world experiences providing DLBCL and FL care to deepen the impact of the education, utilizing a case-based approach to provide a basis for discussion and strategy of the optimal integration of novel therapies to enhance patient-centered care and improve outcomes.

Chair:

±Ê²¹´Ç±ô´ÇÌý³§³Ù°ù²¹³Ù¾±,Ìý²Ñ¶Ù
The University of Texas MD Anderson Cancer Center
Houston,  TX

Speakers:

Douglas Burgoyne, PharmD, FAMCP
University of Utah
Salt Lake City,  UT

±·²¹³Ù³ó²¹²ÔÌý¹ó´Ç·É±ô±ð°ù,Ìý²Ñ¶Ù
The University of Texas MD Anderson Cancer Center
Houston,  TX

Manali Kamdar, MD, MBBS
University of Colorado Cancer Center
Aurora,  CO

±Ê²¹´Ç±ô´ÇÌý³§³Ù°ù²¹³Ù¾±,Ìý²Ñ¶Ù
The University of Texas MD Anderson Cancer Center
Houston,  TX

Eryn Litvinas, PRIME ÎÚÑ»´«Ã½, LLC
Email: [email protected]

A Step-By-Step Approach to CAR T-cell Therapy for RRMM: From Bridging to Sequencing and Adverse Event Management

This program is supported by Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and Legend Biotech

¶Ù±ð³¦±ð³¾²ú±ð°ùÌý06,Ìý2024
3:00 p.m. - 6:00 p.m. Pacific time
San Diego Convention Center
Room 6B

A few years after their emergence, CAR T-cell therapies continue to revolutionize the management of multiple myeloma. Recently, data has emerged about the benefits of and rationale for using CAR T-cell therapies in earlier lines of myeloma therapy. Despite this, some clinicians still hesitate to recommend CAR T-cell therapies to their patients due to misconceptions about the complexity of care management with these therapies. This session aims to bust those myths and get attendees up to speed on the latest data and practical use of CAR T-cell therapies in myeloma care. CAR T-cell therapy experts will discuss and debate their recommended approaches to identifying appropriate patients for CAR T-cell therapy. The dynamic duo will present best practices for optimizing the treatment journey, including strategies for bridging therapies and selecting and sequencing treatment. The discussion will also touch upon key adverse event management considerations, how to optimize treatment in the community setting, and approaches for improving diversity, equity, and inclusion (DEI) in myeloma care.

Engage with faculty in a closing live Q&A session to clarify your challenges in using CAR T-cell therapy in clinical practice. Don't miss this 60-minute whirlwind through CAR T-cell therapy best practices!

Chair:

Jesus G Berdeja, MD
The Greco-Hainsworth Tennessee Oncology Centers for Research
Nashville,  TN

Speaker:

Adriana Rossi, MD, MSc
Mount Sinai
New York,  NY

Emilie Desse, Answers in CME
Email: [email protected]

Addressing Current Questions and Controversies in the Management of Acute Myeloid Leukemia - What Clinicians Want to Know

This program is supported by educational grants from AbbVie Inc, Astellas, and Daiichi Sankyo Inc.

¶Ù±ð³¦±ð³¾²ú±ð°ùÌý06,Ìý2024
3:00 p.m. - 6:00 p.m. Pacific time
Manchester Grand Hyatt San Diego
Seaport Ballroom ABCD

This 2-hour CME-accredited activity – offered to both in-person and virtual attendees – will focus on the management of patients with Acute Myeloid Leukemia (AML). Five clinical investigators will serve as faculty for the program, one of whom will moderate. To create a relevant agenda, prior to the symposium Research To Practice (RTP) will recruit 50 general medical oncologists/hematologists to complete a survey designed to evaluate their educational interests and knowledge deficiencies related to the treatment of AML. During the symposium, selected results from the survey highlighting areas of greatest interest will be presented. The faculty members will then review relevant research findings, discuss evidence-based treatment approaches and provide perspectives on ongoing studies. Actual questions contributed by the survey respondents as well as audience members will be integrated into the proceedings. The live activity will be recorded and developed into an enduring CME resource and promoted by RTP to 46,500 subscribers worldwide.

Chair:

Eytan M. Stein, MD
Memorial Sloan-Kettering Cancer Center
New York,  NY

Speakers:

Alexander E. Perl, MD
University of Pennsylvania
Philadelphia,  PA

Richard M. Stone, MD
Dana-Farber Cancer Institute
Boston,  MA

Eunice S. Wang, MD
Roswell Park Comprehensive Cancer Center
Buffalo,  NY

Andrew H Wei, MBBS, PhD, FRACP, FRCPA
Peter MacCallum Cancer Centre
Melbourne,  VIC, Australia

Sylvia Eriksen, Research To Practice
Email: [email protected]

Addressing Current Questions and Controversies in the Management of Multiple Myeloma - What Clinicians Want to Know

This program is supported by educational grants from GSK, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC and Karyopharm Therapeutics

¶Ù±ð³¦±ð³¾²ú±ð°ùÌý06,Ìý2024
3:00 p.m. - 6:00 p.m. Pacific time
Manchester Grand Hyatt San Diego
Seaport Ballroom EFGH

This 2-hour CME-accredited activity – offered to both in-person and virtual attendees – will focus on the management of patients with multiple myeloma (MM). Five clinical investigators will serve as faculty, one of whom will moderate. Prior to the symposium. Research To Practice (RTP) recruit 4 general medical oncologists/hematologists to consult on the project. The clinicians will participate in a live working group session during which they will voice challenging questions and cases from their practices and help shape the content for the symposium. The entire session will be recorded and video segments will be adapted for presentation during the event. The agenda for the live symposium will be divided into 5 modules. To begin each module, the moderator will play select video excerpts from the working group for the audience and the faculty. Moderated panel discussion will ensue to provide expert perspectives and answers to the questions introduced. A faculty member-led review of related research findings will complete each module. To make the event even more engaging, attendees will use iPads to submit their own questions and cases, which will be introduced and addressed periodically throughout the program. Virtual attendees will have the same capability via the webcast platform.

Chair:

³§²¹²µ²¹°ùÌý³¢´Ç²Ô¾±²¹±ô,Ìý²Ñ¶Ù
Winship Cancer Institute, Emory University
Atlanta,  GA

Speakers:

Philippe Moreau, MD, PhD
University Hospital Hôtel-Dieu
Nantes,  France

Robert Z. Orlowski, MD, PhD
The University of Texas MD Anderson Cancer Center
Houston,  TX

±·´Ç´Ç±è³Ü°ùÌý¸é²¹Âá±ð
Massachusetts General Hospital
Boston,  MA

Paul G. Richardson
Dana-Farber Cancer Institute
Boston,  MA

Sylvia Eriksen, Research To Practice
Email: [email protected]

Bispecific Antibodies: A Playbook for Relapsed/Refractory Follicular Lymphoma

This program is supported by Genmab and AbbVie

¶Ù±ð³¦±ð³¾²ú±ð°ùÌý06,Ìý2024
3:00 p.m. - 6:00 p.m. Pacific time
Marriott Marquis San Diego Marina
Marriott Grand Ballroom 11-13

This will be a 90-minute symposium featuring 2 expert hematologists/oncologists and a patient/patient advocate, as they discuss the role of bispecific antibodies in the treatment of 3L+ R/R FL. Together panelists will review best practices for assessing and applying the latest data on bispecific antibodies, as well as strategies to enhance SDM and patient-centered care.

Chair:

´³´Ç²õ³ó³Ü²¹Ìýµþ°ù´Ç»å²â,Ìý²Ñ¶Ù
Icahn School of Medicine at Mount Sinai
New York,  NY

Speakers:

°­°ù¾±²õ³óÌý±Ê²¹³Ù±ð±ô,Ìý²Ñ¶Ù
Swedish Cancer Institute
Seattle,  WA

³¢´Ç°ù²Ô²¹Ìý°Â²¹°ù·É¾±³¦°ì
Lymphoma Coalition
Mississauga,  ON, CAN

Vikki Chavis, Medscape
Email: [email protected]

Broadening the Impact of Whole-Genome and Transcriptome Sequencing (WG(T)S) in Hematological Malignancies

This program is supported by Illumina

¶Ù±ð³¦±ð³¾²ú±ð°ùÌý06,Ìý2024
3:00 p.m. - 6:00 p.m. Pacific time
San Diego Convention Center
Room 29

This satellite symposium will cover key considerations for incorporating WG(T)S into the workup of patients with acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and other hematologic malignancies. It will feature speakers from industry, academic medical centers and community health systems that have or are in the process of implementing clinical WG(T)S for AML, MDS, and other blood cancers and leverage their expertise to drive important conversations about the current and future clinical utility of WG(T)S in hematologic malignancies. Speakers will provide short presentations covering a variety of topics including, the rationale and benefits of WG(T)S for hematological malignancies, comparison to standard of care testing modalities, workflow and bioinformatic solutions, clinical utilization and ongoing studies at their institutes, and future directions. This workshop will conclude with a question-and-answer session with all speakers to address audience questions.

Chair:

·¡°ù¾±³¦Ìý¶Ù³Ü²Ô³¦²¹±¹²¹²µ±ð,Ìý²Ñ¶Ù
Washington University in St. Louis
St. Louis,  MO

Speakers:

·¡°ù¾±³¦Ìý¶Ù³Ü²Ô³¦²¹±¹²¹²µ±ð,Ìý²Ñ¶Ù
Washington University in St. Louis
St. Louis,  MO

´³²¹³¾±ð²õÌý±á²¹²Ô
Illumina, Inc.
San Diego,  CA

Jonathan J Keats, PhD
TGen
Phoenix,  AZ

²Ñ²¹²ÔÂá²¹Ìý²Ñ±ð²µ²µ±ð²Ô»å´Ç°ù´Ú±ð°ù,Ìý±Ê³ó¶Ù
MLL Munich Leukemia Laboratory
Munich,  Bavaria, Germany

Brian D Piening, PhD
Providence
Portland,  OR

Sugganth Daniel Pillei, MD
Illumina
Irvine,  CA

Richard Rosenquist, MD, PhD
Karolinska Institutet
Stockholm,  Sweden

Pilar Ramos, Illumina
Email: [email protected]

Cases and Conversationsâ„¢: The Rationale for Utilizing Non-Factor Replacement Therapies in Hemophilia Care

This program is supported by Novo Nordisk, Inc.

¶Ù±ð³¦±ð³¾²ú±ð°ùÌý06,Ìý2024
3:00 p.m. - 6:00 p.m. Pacific time
San Diego Convention Center
Room 6A

Hemophilia is an inherited bleeding disorder resulting from a deficiency in plasma coagulation proteins. The WFH recommends prophylactic treatment with replacement clotting factors starting before age 3 for all patients with a severe hemophilia. Prophylaxis has dramatically improved treatment, leading to reduced hospitalizations and absence from school or work and improving health related quality of life (HRQOL). Nevertheless, even with the progress achieved with replacement factors, therapy is costly and burdensome. New approaches to hemophilia treatment are therefore being developed to try and address these concerns. Through engaging case-based discussion and video animations, this accredited symposium will provide learners with insights regarding the pathophysiological pathways underlying hemophilia and new non-factor therapeutic strategies, the limitations in the current standard of care for hemophilia, and the role of non-factor replacement therapy in improving patient outcomes and quality of life.

Chair:

Steven R. Lentz, MD, PhD
University of Iowa
Iowa City,  IA

Speakers:

´¡±ô¾±³¦±ðÌý²Ñ²¹,Ìý²Ñ¶Ù
University of North Carolina
Chapel Hill,  NC

³¢²â²Ô²ÔÌý²Ñ²¹±ô±ð³¦,Ìý²Ñ¶Ù,²Ñ³§³¦
Versiti Blood Research Institute
Wauwatosa,  WI

Kelly McGregor, MJH Events
Email: [email protected]

Clinical assessment of gene therapies for hemophilia A and hemophilia B: Key takeaways for your practice

This program is supported by CSL Behring

¶Ù±ð³¦±ð³¾²ú±ð°ùÌý06,Ìý2024
3:00 p.m. - 6:00 p.m. Pacific time
Marriott Marquis San Diego Marina
Marriott Grand Ballroom 8-9

Join us live and in person for an exciting discussion on assessing gene therapies for hemophilia A and hemophilia B. Hematologists, emergency medicine physicians, nurses, nurse practitioners, physician assistants, and other members of the hemophilia care team will benefit from this interactive and nuanced discussion by an expert panel on the clinical and practical evidence surrounding gene therapies for hemophilia, the differences in gene therapies for hemophilia A and hemophilia B, how to identify eligible candidates for gene therapies for hemophilia A and B, monitor patients with hemophilia who receive gene therapies, and how to counsel patients and colleagues about gene therapies for hemophilia A and B.

Speakers:

´¡³¾²âÌý¶Ù³Ü²Ô²Ô,Ìý²Ñ¶Ù
Nationwide Children's Hospital
Columbus,  OH

Steven W. Pipe, MD
University of Michigan
Ann Arbor,  MI

Doris V. Quon, MD, PhD
Orthopaedic Hospital
Los Angeles,  CA

Vikki Chavis, Medscape
Email: [email protected]

Collaboration In Chronic ITP: Improving Quality Of Life And Patient Outcomes

This program is supported by an independent medical education grant from Sanofi. This activity is jointly provided by USF Health and touchIME

¶Ù±ð³¦±ð³¾²ú±ð°ùÌý06,Ìý2024
3:00 p.m. - 6:00 p.m. Pacific time
San Diego Convention Center
Ballroom 20AB

The management of patients with immune thrombocytopenia (ITP) remains challenging, requiring individualized strategies that incorporate patient preferences with the aim of relieving symptoms and improving wellbeing. Hear a patient's view on the impact of living with ITP and its effect on quality of life, before the expert faculty provide practical insights on current and emerging treatments for chronic ITP and how these may be utilized to improve outcomes for patients, including case-based presentations to review management strategies for different patient profiles. Finally, a panel discussion with all three faculty will focus on shared decision-making and collaboration in the clinic, to give patients with chronic ITP the best possible outcomes. The symposium will include interactivity throughout via audience polling and Q&A sessions.

Chair:

Cindy E Neunert, MD
Columbia University Irving Medical Center
New York,  NY

Speakers:

David J Kuter, MD, DPhil
Massachusetts General Hospital
Boston,  MA

María Eva Mingot-Castellano, MD
Hospital Universitario Virgen del Rocío
Sevilla,  Spain

Lucienne Pratt, touchIME
Email: [email protected]

Complex Cases in the Community Clinic: Managing Diverse Hematologic Malignancies

This program is supported by Sanofi and Incyte Corporation

¶Ù±ð³¦±ð³¾²ú±ð°ùÌý06,Ìý2024
3:00 p.m. - 6:00 p.m. Pacific time
Marriott Marquis San Diego Marina
Marriott Grand Ballroom 2-4

This 120-minute symposium will emulate a typical day for a community hematologist/oncologist, highlighting the diversity of hematologic malignancies and the complex decisions faced daily through a series of patient cases. A panel of expert hematologist/oncologists will evaluate and discuss challenging patient scenarios using recent clinical data, treatment guidelines, and best practices to optimize access to care. The symposium will emphasize patient-centric care and shared decision-making as top priorities, addressing the practical challenges that busy community clinicians encounter. Through this focus on real-world cases and evidence-based strategies, the event aims to enhance the integration of innovative treatments and improve patient outcomes in the community setting.

Chair:

Matthew Matasar, MD, MS
Division of Blood Disorders, Rutgers Cancer Institute of New Jersey and RWJBarnabas Health
New York,  NY

Speakers:

Chan Y. Cheah, MBBS, FRACP, FRCPA, DMSc
Sir Charles Gairdner Hospital and the University of Western Australia
Nedlands,  Australia

Luciano J. Costa, MD,PhD
University of Alabama at Birmingham
Vestavia,  AL

Nisha S. Joseph, MD
Winship Cancer Institute of Emory University
Atlanta,  GA

Chaitra S. Ujjani, MD
Clinical Research Division, Fred Hutch Cancer Center; and Division of Oncology, University of Washington
Seattle,  WA

Vikki Chavis, Medscape
Email: [email protected]

Medical Crossfire®: Bridging Expert Guidance and Evidence-Based Recommendations in the Ever-Evolving Treatment of MF, PV, and ET

This program is supported by MorphoSys and Protagonist Therapeutics Inc.

¶Ù±ð³¦±ð³¾²ú±ð°ùÌý06,Ìý2024
3:00 p.m. - 6:00 p.m. Pacific time
San Diego Convention Center
Ballroom 20CD

Medical Crossfire® is one of PER’s signature educational formats and is a nationally-recognized medical education modality dedicated to improving medical practices and patient care through debate, discussion, and authoritative peer exchange on critical clinical issues. The design of the Medical Crossfire® is based on the understanding that exposure to differing – and sometimes provocative – opinions, insights, and philosophies fuels improved learning and knowledge among healthcare professionals. This Medical Crossfire® formatted satellite program will include a chair and panel of four faculty experts in MPNs, featuring a series of brief didactic presentations, followed by discussion between faculty on key questions and common cases in the field.

To further enhance the integration of recent data into practice, the program will feature an interactive question-and-answer session between the faculty and attendees to emphasize areas of educational need, highlight areas of debate, and illustrate the application of new data in defined clinical situations.

Chair:

Rami S. Komrokji, MD
H. Lee Moffitt Cancer Center and Research Institute
Tampa,  FL

Speakers:

Gabriela S. Hobbs, MD
Massachusetts General Hospital
Boston,  MA

µþ²¹°ù²ú²¹°ù²¹Ìý²Ñ´Ç°ù²¹,Ìý²Ñ¶Ù
Division of Hematology, Ospedale ASST Sette Laghi
Varese,  Italy

Kelly McGregor, MJH Events
Email: [email protected]

Medical Crossfire®: New Horizons in Acute Lymphoblastic Leukemia—How The Experts Apply New Evidence from AYA to Adult Scenarios

This program is supported by Amgen Inc, Autolus Limited, Syndax Pharmaceuticals, Inc, and Takeda Pharmaceuticals U.S.A., Inc.

¶Ù±ð³¦±ð³¾²ú±ð°ùÌý06,Ìý2024
3:00 p.m. - 6:00 p.m. Pacific time
San Diego Convention Center
Room 30

The rapid pace and sheer volume of basic science and therapeutic developments that continue to emerge in the field of ALL create practice and/or educational gaps, particularly for hematology-oncologists and oncology nurses who strive to deliver the best possible care to patients. This Medical Crossfire® will provide an ideal format for the leukemia care team to participate in an open exchange of ideas and viewpoints fostered by a case-based agenda allowing them to review patient scenarios, reflect on how they might handle particular cases, integrate relevant evidence into real-world practice, and compare their patient care approaches with those of experts and peers. Faculty leading discussion of common clinical scenarios and solutions will discuss methods to best integrate the latest therapies into ALL treatment paradigms, address barriers to optimized integration of these novel agents, as well provide best practices for the management of adverse events.

Chair:

·¡±ô¾±²¹²õÌý´³²¹²ú²ú´Ç³Ü°ù,Ìý²Ñ¶Ù
The University of Texas MD Anderson Cancer Center
Houston,  TX

Speakers:

Hagop M. Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Houston,  TX

Aaron C. Logan, MD, PhD
University of California San Francisco
San Francisco,  CA

Rob Pieters, MD, PhD
Princess Máxima Center for Pediatric Oncology
Utrecht,  Netherlands

Claire Roddie, MD, PhD
University College London Hospitals
London,  United Kingdom

Ronald Viggiani, Physicians' ÎÚÑ»´«Ã½ Resource
Email: [email protected]

Sharing Best Practices from the ALL/LBL Clinic: Navigating Patient-Centered Care with Asparaginase Therapies

This program is supported by Jazz Pharmaceuticals, Inc.

¶Ù±ð³¦±ð³¾²ú±ð°ùÌý06,Ìý2024
3:00 p.m. - 6:00 p.m. Pacific time
Marriott Marquis San Diego Marina
Marriott Grand Ballroom 5-6

This 90-min patient-centric symposium will explore navigating the patient journey with asparaginase therapies as part of the treatment strategy for acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LBL). The lively and engaging format will feature a series of video-based clinical vignettes, each modeling best practices in patient-clinician communication, contextualized within a review of the essential role of currently available asparaginase therapies in the optimal management of ALL/LBL. Faculty commentary and expert guidance will focus on how to select therapy, assess treatment efficacy, and recognize and manage the wide range of potential toxicities associated with asparaginase treatment. The expert faculty panel will include an adult hematologist/oncologist, a pediatric hematologist/oncologist, a hematologic oncology nurse specialist, and a patient advocate.

Chair:

±õ²ú°ù²¹³ó¾±³¾Ìý´¡±ô»å´Ç²õ²õ,Ìý²Ñ¶Ù
City of Hope National Medical Center
Duarte,  CA

Speakers:

Sandra Kurtin, PhD, ANP
Clinical Assistant Professor of Medicine
Tucson,  AZ

³¢³Ü°ì±ðÌý²Ñ²¹±ð²õ±ð,Ìý¶Ù°¿
University of Utah, Huntsman Cancer Institute, Primary Children’s Hospital
Salt Lake City,  UT

°ä²¹³Ù±ðÌý°¿'¸é±ð¾±±ô±ô²â
Senior Director Digital Partnerships, Strategic Growth
San Diego, 

Vikki Chavis, Medscape
Email: [email protected]

Unleashing Emerging Therapies to Modify Myelofibrosis Pathogenesis: Shifting the Treatment Paradigm to Target Deeper Clinical and Molecular Responses

This program is supported by PRIME ÎÚÑ»´«Ã½, LLC

¶Ù±ð³¦±ð³¾²ú±ð°ùÌý06,Ìý2024
3:00 p.m. - 6:00 p.m. Pacific time
San Diego Convention Center
Room 6DE

Join expert faculty as they take a deep dive into the latest clinical evidence and practical considerations for the personalized treatment of patients with myelofibrosis (MF) with JAK inhibitors and beyond. Informed by the diverse molecular targets and rationale for emerging MF therapies in late-stage clinical investigation, this satellite symposium will feature a review of the novel mechanisms of action and disease modifying potential of emerging MF therapies that will be reinforced through interactive polling questions and a 2D animation video, as well as expert insights on the potential positioning of these agents into MF treatment plans. Additionally, participants will have access to an up-to-date Myelofibrosis Clinical Trial Pocket Guide alongside the symposium to support the differentiation of the evolving landscape based on mechanisms of action, clinical trial design, and disease-modifying endpoints. Altogether, this satellite symposium is designed to prepare providers for the MF treatment paradigm shift, bringing combination therapy and disease modification to the forefront of patient-centered cares and durable outcomes.

Chair:

´³±ð²¹²Ô²Ô±ðÌý±Ê²¹±ô³¾±ð°ù,Ìý²Ñ¶Ù
Mayo Clinic - Arizona
Scottsdale,  AZ

Speakers:

Douglas Burgoyne, PharmD, FAMCP
University of Utah
Salt Lake City,  UT

Marina Kremyanskaya, MD, PhD
Icahn School of Medicine at Mount Sinai
New York,  NY

´³±ð²¹²Ô²Ô±ðÌý±Ê²¹±ô³¾±ð°ù,Ìý²Ñ¶Ù
Mayo Clinic - Arizona
Scottsdale,  AZ

±Ê²¹²Ô°ì¾±³ÙÌý³Õ²¹³¦³ó³ó²¹²Ô¾±,Ìý²Ñ¶Ù
University of Alabama at Birmingham
Birmingham,  AL

Lindsey Siegel, PRIME ÎÚÑ»´«Ã½, LLC
Email: [email protected]

Accelerating the Adoption of the Latest Evidence on Sequencing Therapies for Multiple Myeloma Across Practice Settings

This program is supported by PRIME ÎÚÑ»´«Ã½, LLC

¶Ù±ð³¦±ð³¾²ú±ð°ùÌý06,Ìý2024
7:00 p.m. - 10:00 p.m. Pacific time
San Diego Convention Center
Room 6DE

Join expert faculty as they take a deep dive into the latest clinical evidence and practical considerations
for treatment of complex cases of patients with multiple myeloma (MM). Informed by real-world data
on challenges regarding selection and sequencing treatment plans and coordinating MM care,
highlighting differences stemming from practice setting. Our panelists will participate in insightful
discussions regarding benefits and risks of different treatment options based on the latest clinical data
and patient characteristics, offering different perspectives and institutional differences, with supportive
slides featuring the current clinical evidence as well as strategies for integrating the best treatments for
individual patients into treatment plans, emphasizing nuances between academic- and community-
based settings. The topics for discussion by the expert faculty panel will be supported by clinical cases
and enhanced by interactive polling questions and live questions submitted by attendees throughout
the presentation. Altogether, this satellite symposium will harness real-world experiences providing MM
care to deepen the impact of the education to enhance treatment selection and care coordination for
the optimal integration of novel therapies in MM across practice settings.

Chair:

Scott R. Goldsmith, MD
City of Hope
Duarte,  CA

Speakers:

²Ñ±ð±ô¾±²õ²õ²¹Ìý´¡±ô²õ¾±²Ô²¹,Ìý²Ñ¶Ù
Moffitt Cancer Center
Tampa,  FL

µþ¾±²Ô´Ç»åÌý¶Ù³ó²¹°ì²¹±ô,Ìý²Ñµþµþ³§
Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin
Milwaukee,  WI

M. Sarfraz Nawaz, MD
Hematology Oncology of Indiana
Carmel,  IN

Eryn Litvinas, PRIME ÎÚÑ»´«Ã½, LLC
Email: [email protected]

How We Do It®: New Combinations Reshaping Treatment Decision-Making in Newly Diagnosed Multiple Myeloma

This program is supported by Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, both are Johnson and Johnson companies, and Sanofi.

¶Ù±ð³¦±ð³¾²ú±ð°ùÌý06,Ìý2024
7:00 p.m. - 10:00 p.m. Pacific time
San Diego Convention Center
Room 30

The live portion of this activity will be presented as a 2.0-hour Friday Satellite Symposium (FSS). The activity is designed to highlight and test participants on the most clinically relevant data in NDMM, provide expert guidance on the interpretation of core concepts, and forecast the clinical impact of recent data sets. The activity will integrate a series of How We Do It® panel discussions alongside didactic presentations. To further enhance the integration of recent data into practice, the program will
feature an interactive question-and-answer session with faculty throughout the
activity to emphasize areas of educational need, highlighting areas of debate, and
illustrating the application of new data in defined clinical situations. To further enhance the integration of recent data into practice, the program will feature an interactive question-and-answer session between the faculty and attendees to emphasize areas of educational need, highlight areas of debate, and illustrate the application of new data in defined clinical situations

Chair:

°¿±ô²¹Ìý³¢²¹²Ô»å²µ°ù±ð²Ô
University of Miami
Miami,  FL

Speakers:

°ä°ù¾±²õ³Ù¾±²Ô²¹Ìý³Ò²¹²õ±è²¹°ù±ð³Ù³Ù´Ç,Ìý²Ñ¶Ù
Duke University Medical Center
Durham,  NC

Katja C. Weisel, MD
Department of Oncology, Hematology and BMT, University Medical Center of Hamburg-Eppendorf
Hamburg,  Germany

Elijah Anseaume, Physicians' ÎÚÑ»´«Ã½ Resource
Email: [email protected]

Show Me the Dataâ„¢: How Do We Navigate the Latest Evidence on Novel Therapies and Trials Across GvHD Prophylaxis, Acute, and Chronic Care?

This program is supported by Incyte Corporation and Mallinckrodt Pharmaceuticals

¶Ù±ð³¦±ð³¾²ú±ð°ùÌý06,Ìý2024
7:00 p.m. - 10:00 p.m. Pacific time
San Diego Convention Center
Room 6A

The live portion of this curriculum will be presented as a 2.5-hour Friday Satellite Symposium (FSS) held prior to the 2024 ASH Annual Meeting. This agenda has been developed in an interactive Show Me the Data format where experts will lead case-based panel discussions regarding the latest clinical advances in treating and managing patients with graft versus host disease (GvHD) with novel treatment approaches and emerging treatment strategies in the context of current paradigms. After each 'decision point' presentation, one faculty from the panel will convene to share their practice preferences and perspectives on the clinical trial data and clinical pearls from their practices. The chair will then challenge the faculty member to show them the data that backs up their decision making. Faculty will be probed on how emerging strategies under investigation may impact future treatment decision making. The program will also feature an interactive question-and-answer session between the faculty and attendees to emphasize areas of educational need, highlight areas of debate, and illustrate the application of new data in defined clinical situations.

Chair:

Corey S. Cutler, MD, MPH
Dana-Farber Cancer Institute
Boston,  MA

Speakers:

Amin M. Alousi, MD
The University of Texas MD Anderson Cancer Center
Houston,  TX

Yi-Bin Chen, MD, MS
Harvard Medical School
Boston,  MA

Carrie L. Kitko, MD
Vanderbilt University Medical Center
Nashville,  TN

Kelly McGregor, MJH Events
Email: [email protected]

Show Me the Data™: Pushing CAR T’s Forward Across Lymphoid Malignancies... Accelerating Access in the Community and Treatment Strategies for the Road Ahead

This program is supported by Autolus Limited and Novartis Pharmaceuticals Inc.

¶Ù±ð³¦±ð³¾²ú±ð°ùÌý06,Ìý2024
7:00 p.m. - 10:00 p.m. Pacific time
San Diego Convention Center
Ballroom 20CD

The live portion of this curriculum will be presented as a 3.0-hour Friday Satellite Symposium (FSS) held prior to the 2024 ASH Annual Meeting. This agenda has been developed in an interactive Show Me the Data format where experts will lead case-based panel discussions regarding the latest clinical advances in treating and managing patients with B-cell malignancies with novel T-cell therapy with novel treatment approaches and emerging treatment strategies in the context of current paradigms. After each 'decision point' presentation, one faculty from the panel will convene to share their practice preferences and perspectives on the clinical trial data and clinical pearls from their practices. The chair will then challenge the faculty member to show them the data that backs up their decision making. Faculty will be probed on how emerging strategies under investigation may impact future treatment decision making. The program will also feature an interactive question-and-answer session between the faculty and attendees to emphasize areas of educational need, highlight areas of debate, and illustrate the application of new data in defined clinical situations.

Chair:

Alexey V. Danilov, MD, PhD
City of Hope National Medical Center
Duarte,  CA

Speakers:

Leidy L. Isenalumhe, MD, MS
Moffitt Cancer Center
Tampa,  FL

Lori A. Leslie, MD
John Theurer Cancer Center, Hackensack University Medical Center
Hackensack,  NJ

Mazyar Shadman, MD, MPH
Fred Hutchinson Cancer Center
Seattle,  WA

Jason R. Westin, MD
The University of Texas MD Anderson Cancer Center
Houston,  TX

Elijah Anseaume, Physicians' ÎÚÑ»´«Ã½ Resource
Email: [email protected]